What is it about?
Dexmedetomidine in Patients Undergoing Endoscopic Resection of Nasopharyngeal Fibroangioma
Featured Image
Photo by Mika Baumeister on Unsplash
Why is it important?
Introduction: Nasopharyngeal Fibroangioma (NPF) is a rare, benign, but locally invasive tumor removed with nasal endoscopy which is minimally invasive and provides a magnified view of the tumor. Hypotensive anaesthesia technique is required to assist in decreasing blood loss and providing bloodless clear field to facilitate surgery. Aim: To compare Nitroglycerin and Dexmedetomidine groups for hypotensive anaesthesia in patients undergoing endoscopic resection of Nasopharyngeal Fibroangioma. Materials and Methods: This is a prospective, randomized, single blinded study conducted on 40 patients between the age group of 10-20 years undergoing endoscopic resection of Nasopharyngeal Fibroangioma. The patients were randomly divided into two groups of 20 patients each. Group D – Patients who received ‘Dexmedetomidine’ Group N – Patients who received ‘Nitroglycerin’. Results: There was no statistically significant difference between the two groups regarding mean arterial pressures. There was statistically significant difference between the two drug groups regarding pulse rate. The mean pulse rate in Dexmedetomidine group was significantly less than in Nitroglycerin group. The average blood loss was more with Nitroglycerin when compared to Dexmedetomidine. Conclusion: Nitroglycerine and Dexmedetomidine can be used safely for maintaining hypotensive anaesthesia to achieve the target mean arterial pressure around 60-70 mm/Hg. The blood loss was significantly less in Dexmedetomidine group. Dexmedetomidine was superior to Nitroglycerin in reducing blood loss during the resection.
Perspectives
Read the Original
This page is a summary of: Comparative Study of Nitroglycerin and Dexmedetomidine in Patients Undergoing Endoscopic Resection of Nasopharyngeal Fibroangioma, Indian Journal of Anaesthesia and Analgesia, January 2019, Red Flower Publication Private, Ltd.,
DOI: 10.21088/ijaa.2349.8471.6119.30.
You can read the full text:
Contributors
The following have contributed to this page